Latest News

Nirsevimab Cuts RSV Risk in Healthy Newborns: Daily Dose / image credit: ©New Africa/AdobeStock
Nirsevimab Cuts RSV Risk in Healthy Newborns: Daily Dose

August 12th 2025

Your daily dose of the clinical news you may have missed.

FDA Accepts Priority Review of Gepotidacin for Oral Treatment of Uncomplicated Urogenital Gonorrhea / Image credit: ©MohamadFaisal/AdobeStock
FDA Accepts Gepotidacin for Priority Review for the Treatment of Uncomplicated Urogenital Gonorrhea

August 11th 2025

Nirsevimab Highly Effective in Preventing RSV-Related LRTD in Healthy Term Infants, Real-World Study Finds
Nirsevimab Highly Effective in Preventing RSV-Related LRTD in Healthy Term Infants, Real-World Study Finds

July 25th 2025

Influenza Vaccination Reduces Disease Burden in Both Vaccinated and Unvaccinated, Modeling Study Finds
Influenza Vaccination Reduces Disease Burden in Both Vaccinated and Unvaccinated, Modeling Study Finds

July 24th 2025

Phase 3 Trials Begin for Once-Monthly Oral HIV Prevention Pill
Phase 3 Trials Begin for Once-Monthly Oral HIV Prevention Pill

July 17th 2025

Latest CME Events & Activities

More News

© 2025 MJH Life Sciences

All rights reserved.